Physician profile
Elham Abboud
NPI 1164409447
$1,920.99
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $136 · 2021: $122 · 2022: $127 · 2023: $399 · 2024: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,176.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $328.10 | 2019-2024 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $290.61 | 2019-2024 | |
| Foundation Medicine, INC. | $269.46 | 2019-2023 | |
| Lilly USA, LLC | $255.61 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Pfizer INC. | $121.97 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $97.70 | 2019-2020 | |
| Daiichi Sankyo INC. | $76.39 | 2020-2023 | Injectafer |
| Eisai INC. | $70.83 | 2023-2024 | |
| Springworks Therapeutics, INC. | $68.67 | 2024 | Ogsiveo |
| Astellas Pharma US INC | $47.14 | 2023-2024 | Xtandi |
| Blueprint Medicines Corporation | $47.00 | 2023-2024 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $44.93 | 2024 | Fruzaqla |
| Ortho-Clinical Diagnostics, INC. | $44.32 | 2021-2022 | |
| Janssen Biotech, INC. | $35.69 | 2024 | Rybrevant |
| Cumberland Pharmaceuticals, INC. | $30.20 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $25.35 | 2023 | Padcev |
| Cepheid | $18.86 | 2021 | |
| Siemens Medical Solutions USA, INC. | $17.19 | 2023 | Rapidpoint 400/405/500 Wash/Waste Cartridge |
| Medline Industries Lp | $15.62 | 2024 | Medline Industries, INC. |
| Exelixis INC. | $15.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elham Abboud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.